Gerald Klein, MD 

Chief Medical Officer

Dr. Gerald Klein joins APIE-Therapeutics as co-Chief Medical Officer to further advance the Idiopathic Pulmonary Fibrosis (IPF) and Heart Failure (HF) therapies from pre-clinical into Clinical Trials, as well as programs entering the preclinical stage.  He is  a board certified Allergist and Immunologist, and a board certified Pediatrician.  He was a professor of Medicine and Pediatrics (Division of Basic and Applied Immunology) at the University of California, Irvine-CA.   Dr. Klein was the founder of the San Diego Clinical Research Association, (SDCRA) where he served as CEO and CMO.  SDCRA conducted studies in Dermatology, Infectious Disease, Neurology, Cardiology, Psychiatry, Nephrology, Pulmonology, Women’s Health, Surgery, and Allergy.  SDCRA was sold to Quintiles, where Dr. Klein, joined as the SVP of Global Medical Affairs and Drug Development.  After Quintiles, he joined Talecris (Grifols) as the Chief Medical Officer, where he was instrumental in creating a comprehensive safety and pharmacovigilance plan and helping the company gain a new neurological indication.  After his tenure at Talecris, he was founder and CEO of Entera Health Inc., a biotherapeutics company, where he created and managed both the clinical development and medical affairs programs.  Dr. Klein has also been CMO / Executive of Medical and Clinical Affairs at several specialty biopharmaceutical companies including:  Dey/MerckKgAa,  Clingenix (respiratory and allergy), Pharmacogenomic (diabetes)/CRO, Specialty Labs/Pathway Diagnosis, and Oxygen Biotherapeutic/Tanex.  Additionally, Dr. Klein has been on the Board of Directors of Nano Corp and Oxygen Biotherapeutics.  He is currently Co-Founder and Principal of MedSurgPI LLC.   

 

Dr. Gerald Klein holds an MD from University of Brussels Medical School, Belgium.

© 2020 by Apie Therapeutics. 

  • LinkedIn